Skip to content

Other at other companies

Charles River Laboratories logo
Charles River LaboratoriesCRL
0%

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.79B+125%

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationCrossBorderOtherPercent.

The official record: Zymeworks’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is Zymeworks's other?
Zymeworks (ZYME) reported other of 0% in Q4 2025.
What does other mean?
This metric represents the impact of foreign tax rate differentials on the company's effective tax rate compared to the domestic statutory rate. It highlights the tax benefit or burden resulting from operations in jurisdictions with tax regimes different from the company's home country. Investors use this to assess the tax efficiency of the company's global operational footprint.